Skip to main content

CJC-1295 Therapy

Meaning

CJC-1295 therapy involves the subcutaneous administration of a synthetic peptide analog, specifically a Growth Hormone-Releasing Hormone (GHRH) mimetic, which is engineered to stimulate the pituitary gland’s sustained, physiological release of its own endogenous Growth Hormone (GH). This long-acting peptide is uniquely characterized by its Drug Affinity Complex (DAC) modification, which significantly extends its half-life in the systemic circulation, allowing for a far less frequent dosing schedule compared to the native GHRH. The core clinical goal of this therapeutic approach is to naturally elevate both GH and Insulin-like Growth Factor 1 (IGF-1) levels to support various anabolic physiological functions related to improved body composition, enhanced tissue recovery, and overall metabolic vitality.